Blueshift Asset Management’s TG Therapeutics TGTX Stock Holding History

Blueshift Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,778	Closed	-$321K	–	651
2025 Q4	$321K	Buy	+10,778	New	+$352K	0.09%	311
2023 Q4	–	Sell	-61,075	Closed	-$511K	–	368
2023 Q3	$511K	Buy	+61,075	New	+$851K	0.3%	95
2022 Q4	–	Sell	-12,914	Closed	-$76K	–	635
2022 Q3	$76K	Buy	+12,914	New	+$84.7K	0.02%	565
2021 Q3	–	Sell	-18,900	Closed	-$733K	–	1296
2021 Q2	$733K	Buy	+18,900	New	+$742K	0.04%	440

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Blueshift Asset Management's TGTX Position: Q1 2026 in Review

Blueshift Asset Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 10,778 shares — an estimated $321K sold.

Blueshift Asset Management first reported a position in TGTX in Q2 2021 and held it in 4 quarters. The position peaked at $733K in Q2 2021. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Blueshift Asset Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Blueshift Asset Management sold 10,778 TG Therapeutics shares in Q1 2026, an estimated $321K.
Blueshift Asset Management first reported a position in TG Therapeutics in Q2 2021 and held it in 4 quarters.
Blueshift Asset Management's TG Therapeutics position peaked at $733K in Q2 2021.
365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Blueshift Asset Management's 13F filing for Q1 2026, filed 14 May 2026.